A citation-based method for searching scientific literature

Bryony E Langford, Marc Evans, Tao Haskins-Coulter, Molly O'Connor, Harriet E O Cant, Lucy A Eddowes, Christopher Edmonds, Amarjeet Tank. Diabetes Obes Metab 2020
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N. Engl. J. Med. 2019
875
100


A new model for 5-year risk of cardiovascular disease in Type 1 diabetes; from the Swedish National Diabetes Register (NDR).
J Cederholm, K Eeg-Olofsson, B Eliasson, B Zethelius, S Gudbjörnsdottir. Diabet. Med. 2011
33
100


The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
M Charokopou, P McEwan, S Lister, L Callan, K Bergenheim, K Tolley, R Postema, R Townsend, M Roudaut. Diabet. Med. 2015
19
100

Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
Serge Jabbour, Jochen Seufert, Andre Scheen, Clifford J Bailey, Cathrina Karup, Anna M Langkilde. Diabetes Obes Metab 2018
56
100

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
D M Nathan, S Genuth, J Lachin, P Cleary, O Crofford, M Davis, L Rand, C Siebert. N. Engl. J. Med. 1993
100



The Impact of Diabetes-Related Complications on Preference-Based Measures of Health-Related Quality of Life in Adults with Type I Diabetes.
Tessa Peasgood, Alan Brennan, Peter Mansell, Jackie Elliott, Hasan Basarir, Jen Kruger. Med Decis Making 2016
14
100


Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Mikhail Kosiborod, Carolyn S P Lam, Shun Kohsaka, Dae Jung Kim, Avraham Karasik, Jonathan Shaw, Navdeep Tangri, Su-Yen Goh, Marcus Thuresson, Hungta Chen,[...]. J. Am. Coll. Cardiol. 2018
140
100

SGLT2 Inhibitors May Predispose to Ketoacidosis.
Simeon I Taylor, Jenny E Blau, Kristina I Rother. J. Clin. Endocrinol. Metab. 2015
211
100


The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes Mellitus.
Phil McEwan, Hayley Bennett, Jonathan Fellows, Jennifer Priaulx, Klas Bergenheim. PLoS ONE 2016
7
100


Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives.
Hongyu Qiu, Aleksandra Novikov, Volker Vallon. Diabetes Metab. Res. Rev. 2017
48
100

Pre-existing diabetes significantly increases the risk of graft failure and mortality following renal transplantation.
David J Taber, Holly B Meadows, Nicole A Pilch, Kenneth D Chavin, Prabhakar K Baliga, Leonard E Egede. Clin Transplant 2013
17
100

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
Kenneth W Mahaffey, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Elisa Fabbrini, Tao Sun, Qiang Li,[...]. Circulation 2018
144
100

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, John P Wilding, Kamlesh Khunti, Reinhard W Holl, Anna Norhammar, Kåre I Birkeland, Marit Eika Jørgensen, Marcus Thuresson,[...]. Circulation 2017
311
100



Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2018
53
100

Diabetic ketoacidosis in adults.
Shivani Misra, Nick S Oliver. BMJ 2015
12
100

Adverse effects and safety of SGLT-2 inhibitors.
S Halimi, B Vergès. Diabetes Metab. 2014
33
100

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
Chantal Mathieu, Paresh Dandona, Pieter Gillard, Peter Senior, Christoph Hasslacher, Eiichi Araki, Marcus Lind, Stephen C Bain, Serge Jabbour, Niki Arya,[...]. Diabetes Care 2018
75
100



Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
David M Nathan, Patricia A Cleary, Jye-Yu C Backlund, Saul M Genuth, John M Lachin, Trevor J Orchard, Philip Raskin, Bernard Zinman. N. Engl. J. Med. 2005
100



Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.
Agata Ptaszynska, Kristina M Johnsson, Shamik J Parikh, Tjerk W A de Bruin, Anne Marie Apanovitch, James F List. Drug Saf 2014
69
100

A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus.
Martin Henriksson, Ramandeep Jindal, Catarina Sternhufvud, Klas Bergenheim, Elisabeth Sörstadius, Michael Willis. Pharmacoeconomics 2016
14
100

Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 and Type 2 Diabetes in England.
Robert Brett McQueen, Marc D Breton, Joyce Craig, Hayden Holmes, Melanie D Whittington, Markus A Ott, Jonathan D Campbell. J Diabetes Sci Technol 2018
5
100

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
113
100


Assessing the cost-effectiveness of type 1 diabetes interventions: the Sheffield type 1 diabetes policy model.
P Thokala, J Kruger, A Brennan, H Basarir, A Duenas, A Pandor, M Gillett, J Elliott, S Heller. Diabet. Med. 2014
19
100

Impact of Excessive Weight Gain on Cardiovascular Outcomes in Type 1 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study.
Jonathan Q Purnell, Barbara H Braffett, Bernard Zinman, Rose A Gubitosi-Klug, William Sivitz, John P Bantle, Georgia Ziegler, Patricia A Cleary, John D Brunzell. Diabetes Care 2017
27
100

Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria.
Suzanne Geerlings, Vivian Fonseca, David Castro-Diaz, James List, Shamik Parikh. Diabetes Res. Clin. Pract. 2014
107
100

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N. Engl. J. Med. 2015
100

Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
M Charokopou, P McEwan, S Lister, L Callan, K Bergenheim, K Tolley, R Postema, R Townsend, M Roudaut. BMC Health Serv Res 2015
21
100



Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes.
Craig J Currie, Christopher Ll Morgan, Chris D Poole, Peter Sharplin, Morten Lammert, Phil McEwan. Curr Med Res Opin 2006
173
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.